Cohen M M
Prostaglandins. 1981;21 Suppl:155-60. doi: 10.1016/0090-6980(81)90132-5.
The purpose of this study was to determine the minimum effective protective dose of PGE2 given concurrently with ASA. Thirty-two adult male volunteers completed a double-blind placebo-controlled experiment. Fecal blood loss was measured by the 51Cr technique for 15 days. ASA (650 mg four times daily) was given for the middle 5 days and in addition subjects received PGE2 orally in doses of 0.04 mg, 0.25 mg or 0.5 mg or placebo four times daily. In the control group ASA caused a significant increase in fecal blood and this was reduced in a dose-dependent manner by the three doses of PGE2 employed. Serum salicylate was elevated similarly in all four groups. Four subjects receiving 0.5 mg PGE2 experienced mild transient side effects. It is concluded that concurrent treatment with oral PGE2 affords significant dose-dependent protection against ASA-induced gastrointestinal blood loss and that even a dose of 0.04 mg four times daily provided some protection.
本研究的目的是确定与阿司匹林同时使用时PGE2的最小有效保护剂量。32名成年男性志愿者完成了一项双盲安慰剂对照实验。采用51Cr技术测量15天的粪便失血量。在中间5天给予阿司匹林（650毫克，每日4次），此外，受试者每天口服4次剂量为0.04毫克、0.25毫克或0.5毫克的PGE2或安慰剂。在对照组中，阿司匹林导致粪便出血量显著增加，而所使用的三种剂量的PGE2均以剂量依赖的方式使其减少。所有四组的血清水杨酸水平均有类似升高。4名接受0.5毫克PGE2的受试者出现了轻度短暂的副作用。结论是，口服PGE2同时治疗可对阿司匹林引起的胃肠道失血提供显著的剂量依赖性保护，且即使每日4次剂量为0.04毫克也能提供一定保护。
